155 related articles for article (PubMed ID: 26116359)
21. Tumor-Preferential Induction of Immune Responses and Epidermal Cell Death in Actinic Keratoses by Ingenol Mebutate.
Emmert S; Haenssle HA; Zibert JR; Schön M; Hald A; Hansen MH; Litman T; Schön MP
PLoS One; 2016; 11(9):e0160096. PubMed ID: 27612149
[TBL] [Abstract][Full Text] [Related]
22. Extracellular ATP activates the PLC/PKC/ERK signaling pathway through the P2Y2 purinergic receptor leading to the induction of early growth response 1 expression and the inhibition of viability in human endometrial stromal cells.
Chang SJ; Tzeng CR; Lee YH; Tai CJ
Cell Signal; 2008 Jul; 20(7):1248-55. PubMed ID: 18434089
[TBL] [Abstract][Full Text] [Related]
23. IL-1 Contributes to the Anti-Cancer Efficacy of Ingenol Mebutate.
Le TT; Skak K; Schroder K; Schroder WA; Boyle GM; Pierce CJ; Suhrbier A
PLoS One; 2016; 11(4):e0153975. PubMed ID: 27100888
[TBL] [Abstract][Full Text] [Related]
24. Ingenol mebutate induces a tumor cell-directed inflammatory response and antimicrobial peptides thereby promoting rapid tumor destruction and wound healing.
Braun SA; Baran J; Schrumpf H; Buhren BA; Bölke E; Homey B; Gerber PA
Eur J Med Res; 2018 Sep; 23(1):45. PubMed ID: 30266096
[TBL] [Abstract][Full Text] [Related]
25. Nobiletin induces inhibitions of Ras activity and mitogen-activated protein kinase kinase/extracellular signal-regulated kinase signaling to suppress cell proliferation in C6 rat glioma cells.
Aoki K; Yokosuka A; Mimaki Y; Fukunaga K; Yamakuni T
Biol Pharm Bull; 2013; 36(4):540-7. PubMed ID: 23546290
[TBL] [Abstract][Full Text] [Related]
26. Widdrol-induced lipolysis is mediated by PKC and MEK/ERK in 3T3-L1 adipocytes.
Jeong HY; Yun HJ; Kim BW; Lee EW; Kwon HJ
Mol Cell Biochem; 2015 Dec; 410(1-2):247-54. PubMed ID: 26359088
[TBL] [Abstract][Full Text] [Related]
27. Protein kinase C-alpha coordinately regulates cytosolic phospholipase A(2) activity and the expression of cyclooxygenase-2 through different mechanisms in mouse keratinocytes.
Wang HQ; Kim MP; Tiano HF; Langenbach R; Smart RC
Mol Pharmacol; 2001 Apr; 59(4):860-6. PubMed ID: 11259631
[TBL] [Abstract][Full Text] [Related]
28. Histamine H1 receptor antagonist blocks histamine-induced proinflammatory cytokine production through inhibition of Ca2+-dependent protein kinase C, Raf/MEK/ERK and IKK/I kappa B/NF-kappa B signal cascades.
Matsubara M; Tamura T; Ohmori K; Hasegawa K
Biochem Pharmacol; 2005 Feb; 69(3):433-49. PubMed ID: 15652235
[TBL] [Abstract][Full Text] [Related]
29. Effective treatment of squamous cell carcinomas with ingenol mebutate gel in immunologically intact SKH1 mice.
Cozzi SJ; Le TT; Ogbourne SM; James C; Suhrbier A
Arch Dermatol Res; 2013 Jan; 305(1):79-83. PubMed ID: 22871992
[TBL] [Abstract][Full Text] [Related]
30. Safety and tolerability of ingenol mebutate in the treatment of actinic keratosis.
Berman B
Expert Opin Drug Saf; 2015; 14(12):1969-78. PubMed ID: 26524598
[TBL] [Abstract][Full Text] [Related]
31. Ingenol Disoxate: A Novel 4-Isoxazolecarboxylate Ester of Ingenol with Improved Properties for Treatment of Actinic Keratosis and Other Non-Melanoma Skin Cancers.
Bertelsen M; Stahlhut M; Grue-Sørensen G; Liang X; Christensen GB; Skak K; Engell KM; Högberg T
Dermatol Ther (Heidelb); 2016 Dec; 6(4):599-626. PubMed ID: 27503482
[TBL] [Abstract][Full Text] [Related]
32. Ingenol mebutate: a promising treatment for actinic keratoses and nonmelanoma skin cancers.
Gupta AK; Paquet M
J Cutan Med Surg; 2013; 17(3):173-9. PubMed ID: 23673300
[TBL] [Abstract][Full Text] [Related]
33. Ingenol mebutate treatment in actinic keratosis - clinical effectiveness and potential side effects.
Lesiak A; Maćkowska A; Bednarski IA; Kolano P; Olejniczak-Staruch I; Woźniacka A; Sieniawska J; Narbutt J
Postepy Dermatol Alergol; 2019 Aug; 36(4):468-471. PubMed ID: 31616223
[TBL] [Abstract][Full Text] [Related]
34. Activation of the RAF/mitogen-activated protein/extracellular signal-regulated kinase kinase/extracellular signal-regulated kinase pathway mediates apoptosis induced by chelerythrine in osteosarcoma.
Yang R; Piperdi S; Gorlick R
Clin Cancer Res; 2008 Oct; 14(20):6396-404. PubMed ID: 18927278
[TBL] [Abstract][Full Text] [Related]
35. PEP005 (ingenol mebutate) gel, a novel agent for the treatment of actinic keratosis: results of a randomized, double-blind, vehicle-controlled, multicentre, phase IIa study.
Siller G; Gebauer K; Welburn P; Katsamas J; Ogbourne SM
Australas J Dermatol; 2009 Feb; 50(1):16-22. PubMed ID: 19178487
[TBL] [Abstract][Full Text] [Related]
36. Quality of life and side effects in patients with actinic keratosis treated with ingenol mebutate: a pilot study.
Jubert-Esteve E; Del Pozo-Hernando LJ; Izquierdo-Herce N; Bauzá-Alonso A; Martín-Santiago A; Jones-Caballero M
Actas Dermosifiliogr; 2015 Oct; 106(8):644-50. PubMed ID: 26130156
[TBL] [Abstract][Full Text] [Related]
37. Biological Effects of Ingenol Mebutate Gel in Moderate to Severe Actinic Fields Assessed by Reflectance Confocal Microscopy: A Phase I Study.
Ulrich M; Lange-Asschenfeldt S; Skak K; Skov T; Østerdal ML; Röwert-Huber HJ; Zibert JR; Stockfleth E
J Drugs Dermatol; 2016 Oct; 15(10):1181-1189. PubMed ID: 27741334
[TBL] [Abstract][Full Text] [Related]
38. Alpha 3 beta 1 integrin promotes keratinocyte cell survival through activation of a MEK/ERK signaling pathway.
Manohar A; Shome SG; Lamar J; Stirling L; Iyer V; Pumiglia K; DiPersio CM
J Cell Sci; 2004 Aug; 117(Pt 18):4043-54. PubMed ID: 15280429
[TBL] [Abstract][Full Text] [Related]
39. Ingenol mebutate gel for actinic keratosis.
Lebwohl M; Swanson N; Anderson LL; Melgaard A; Xu Z; Berman B
N Engl J Med; 2012 Mar; 366(11):1010-9. PubMed ID: 22417254
[TBL] [Abstract][Full Text] [Related]
40. Relapse of pemphigus vulgaris after topical application of ingenol mebutate.
Russo I; Ferrazzi A; Alaibac M
Clin Exp Dermatol; 2016 Aug; 41(6):664-6. PubMed ID: 27381839
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
